Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 2
1962 2
1963 1
1966 1
1967 1
1968 3
1981 2
1984 2
1985 1
1987 2
1988 2
1989 1
1991 2
1992 1
1993 3
1994 3
1995 5
1996 1
1997 2
1998 1
1999 1
2000 4
2001 2
2002 2
2003 3
2004 1
2005 6
2006 4
2007 8
2008 16
2009 14
2010 12
2011 26
2012 44
2013 37
2014 46
2015 35
2016 33
2017 37
2018 32
2019 32
2020 72
2021 80
2022 91
2023 88
2024 48

Text availability

Article attribute

Article type

Publication date

Search Results

731 results

Results by year

Filters applied: . Clear all
Page 1
Pancreas Cancer-Associated Pain Management.
Coveler AL, Mizrahi J, Eastman B, Apisarnthanarax SJ, Dalal S, McNearney T, Pant S; Precision Promise Consortium. Coveler AL, et al. Among authors: pant s. Oncologist. 2021 Jun;26(6):e971-e982. doi: 10.1002/onco.13796. Epub 2021 May 12. Oncologist. 2021. PMID: 33885205 Free PMC article. Review.
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.
Wainberg ZA, Melisi D, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardière C, Dean A, Kiss I, Lee WJ, Goetze TO, Van Cutsem E, Paulson AS, Bekaii-Saab T, Pant S, Hubner RA, Xiao Z, Chen H, Benzaghou F, O'Reilly EM. Wainberg ZA, et al. Among authors: pant s. Lancet. 2023 Oct 7;402(10409):1272-1281. doi: 10.1016/S0140-6736(23)01366-1. Epub 2023 Sep 11. Lancet. 2023. PMID: 37708904 Free article. Clinical Trial.
Access to effective antimicrobials: a worldwide challenge.
Laxminarayan R, Matsoso P, Pant S, Brower C, Røttingen JA, Klugman K, Davies S. Laxminarayan R, et al. Among authors: pant s. Lancet. 2016 Jan 9;387(10014):168-75. doi: 10.1016/S0140-6736(15)00474-2. Epub 2015 Nov 18. Lancet. 2016. PMID: 26603918 Review.
Treatment sequencing in metastatic colorectal cancer.
Modest DP, Pant S, Sartore-Bianchi A. Modest DP, et al. Among authors: pant s. Eur J Cancer. 2019 Mar;109:70-83. doi: 10.1016/j.ejca.2018.12.019. Epub 2019 Jan 25. Eur J Cancer. 2019. PMID: 30690295 Review.
Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation.
Bekaii-Saab TS, Yaeger R, Spira AI, Pelster MS, Sabari JK, Hafez N, Barve M, Velastegui K, Yan X, Shetty A, Der-Torossian H, Pant S. Bekaii-Saab TS, et al. Among authors: pant s. J Clin Oncol. 2023 Sep 1;41(25):4097-4106. doi: 10.1200/JCO.23.00434. Epub 2023 Apr 26. J Clin Oncol. 2023. PMID: 37099736 Free PMC article.
Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer.
Schalck A, Sakellariou-Thompson D, Forget MA, Sei E, Hughes TG, Reuben A, Bai S, Hu M, Kumar T, Hurd MW, Katz MHG, Tzeng CD, Pant S, Javle M, Fogelman DR, Maitra A, Haymaker CL, Kim MP, Navin NE, Bernatchez C. Schalck A, et al. Among authors: pant s. Cancer Discov. 2022 Oct 5;12(10):2330-2349. doi: 10.1158/2159-8290.CD-21-1248. Cancer Discov. 2022. PMID: 35849783 Free PMC article.
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon DA, Massard C, Minchom A, Lugowska I, Carranza O, Arnold D, Gutierrez M, Winter H, Stuyckens K, Crow L, Najmi S, Hammond C, Thomas S, Santiago-Walker A, Triantos S, Sweiti H, Loriot Y; RAGNAR Investigators. Pant S, et al. Lancet Oncol. 2023 Aug;24(8):925-935. doi: 10.1016/S1470-2045(23)00275-9. Lancet Oncol. 2023. PMID: 37541273 Free PMC article. Clinical Trial.
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.
Harding JJ, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, Bao L, Sun HC, Macarulla T, Xie F, Metges JP, Ying J, Bridgewater J, Lee MA, Tejani MA, Chen EY, Kim DU, Wasan H, Ducreux M, Bao Y, Boyken L, Ma J, Garfin P, Pant S; HERIZON-BTC-01 study group. Harding JJ, et al. Among authors: pant s. Lancet Oncol. 2023 Jul;24(7):772-782. doi: 10.1016/S1470-2045(23)00242-5. Epub 2023 Jun 2. Lancet Oncol. 2023. PMID: 37276871 Clinical Trial.
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.
Meric-Bernstam F, Beeram M, Hamilton E, Oh DY, Hanna DL, Kang YK, Elimova E, Chaves J, Goodwin R, Lee J, Nabell L, Rha SY, Mayordomo J, El-Khoueiry A, Pant S, Raghav K, Kim JW, Patnaik A, Gray T, Davies R, Ozog MA, Woolery J, Lee KW. Meric-Bernstam F, et al. Among authors: pant s. Lancet Oncol. 2022 Dec;23(12):1558-1570. doi: 10.1016/S1470-2045(22)00621-0. Epub 2022 Nov 16. Lancet Oncol. 2022. PMID: 36400106 Clinical Trial.
731 results